Virtus LifeSci Biotech Clinical Trials ETF (BBC)

NYSEARCA: BBC · IEX Real-Time Price · USD
25.05
-0.98 (-3.78%)
At close: Dec 5, 2022 3:37 PM
25.15
+0.11 (0.42%)
After-hours: Dec 5, 2022 6:30 PM EST
-3.78%
Assets $18.22M
NAV $26.03
Expense Ratio 0.79%
PE Ratio n/a
Shares Out 700,000
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date n/a
1-Year Return -33.26%
Volume 2,061
Open 25.66
Previous Close 26.03
Day's Range 25.05 - 25.66
52-Week Low 17.77
52-Week High 40.86
Beta 1.12
Holdings 122
Inception Date Dec 16, 2014

About BBC

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.

Asset Class Equity
Sector Biotech
Region North America
Stock Exchange NYSEARCA
Ticker Symbol BBC
Issuer Website Virtus
Index Tracked LifeSci Biotechnology Clinical Trials

Top 10 Holdings

18.35% of assets
Name Symbol Weight
Akero Therapeutics, Inc. AKRO 3.23%
Immunovant, Inc. IMVT 2.44%
Inhibrx, Inc. INBX 2.18%
Prothena Corporation PLC PRTA 1.62%
Imago BioSciences, Inc. IMGO 1.60%
Seres Therapeutics, Inc. MCRB 1.51%
DICE Therapeutics, Inc. DICE 1.51%
Vaxcyte, Inc. PCVX 1.45%
IVERIC bio, Inc. ISEE 1.40%
Bicycle Therapeutics PLC BCYC 1.39%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Dec 20, 2017 $0.29724 Dec 27, 2017
Dec 21, 2015 $0.14733 Dec 29, 2015
Full Dividend History

News

What Slump? 4 Sector ETFs Up At Least 14% in Q3

Though Wall Street delivered a subdued performance in Q3, these sector ETFs offered double-digit returns.

2 months ago - Zacks Investment Research

4 Best ETF Areas of Last Week That Are Up At Least 5%

Wall Street was downbeat last week led by Apple after it dropped plans to boost production of its new iPhones.

Other symbols: CYAIBRNSGDMSILTWEBUUP
2 months ago - Zacks Investment Research

5 Best Areas of Q3 of 2022 & Their Top ETFs

These ETF areas won in the third quarter of 2022.

Other symbols: BBPEWZSMLPAQCLNSMINURA
2 months ago - Zacks Investment Research

Biotech Wins Last Week: 5 Best ETFs

The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.

Other symbols: BBPPFESBIOXBI
4 months ago - Zacks Investment Research

Stocks' Best Month Since 2020: Top ETF Areas of July

Wall Street logged the best month since November 2020 in July. These are the winning ETFs.

Other symbols: CTEXIGNITBPTFTANXHB
4 months ago - Zacks Investment Research

3 ETFs Braving Inflationary Fears in Past Three Months

These ETFs have braved the inflationary fears in the past three months and topped the S&P 500.

Other symbols: TAN
4 months ago - Zacks Investment Research

5 ETFs Riding High on the Biotech Comeback

Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.

Other symbols: BBPCNCRSBIOXBI
5 months ago - Zacks Investment Research

Pharma & Biotech ETFs at One-Month High: Here's Why

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

5 months ago - Zacks Investment Research

Biotech ETFs Are Making a Comeback

Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market. Over the past month, the Virtus LifeSci Biotech Cl...

Other symbols: BBPSBIOXBI
5 months ago - ETF Trends

Biotech ETF Tops in June: 5 Stocks That Outperform

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' barga...

Other symbols: DAWNKZRLYELMRTXRPTX
5 months ago - Zacks Investment Research

4 Sector ETFs That Survived Market Turmoil in June

June has proved to be a brutal month for the stock market. The combination of factors such as decades-high inflation, the Russia-Ukraine conflict and Fed?

Other symbols: BTCRLITRAYS
5 months ago - Zacks Investment Research

ETFs Winners of S&P 500's Second Best Week in 2022

The S&P 500 advanced more than 3% on Friday, logging back-to-back days of gains and marking its first weekly advance since late May.

Other symbols: ARKGARKKARKWIPOWCLDXBI
5 months ago - Zacks Investment Research

Biotech ETFs Strengthen as Bristol Myers Squibb Buys Turning Point

Biotechnology sector-related exchange traded funds were in a bright spot on Friday after Bristol Myers Squibb Co. (NYSE: BMY) said it will acquire drug developers Turning Point Therapeutics (NasdaqGS: T...

Other symbols: XBI
6 months ago - ETF Trends

Size Up SBIO as Biotech Catalysts Emerge

Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year, but interested investors have some potential positive facts to ponder. First, biotech va...

Other symbols: BBHIBBSBIO
6 months ago - ETF Trends

Betting on Biotech Bear Market Expiration Date

Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader d...

Other symbols: BBHIBBSBIO
6 months ago - ETF Trends

Positioning for Biotech Bounceback

Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy trend will end soon. Investors willing to take that b...

Other symbols: BBHIBBSBIO
8 months ago - ETF Trends

Top and Flop ETFs of Q1

We have highlighted the three ETFs each from the best and worst performing zones of first-quarter 2022.

Other symbols: OIHXME
8 months ago - Zacks Investment Research

Biotech Stocks, ETFs Starting to Look Healthier

Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALPS ...

Other symbols: BBHIBBSBIO
9 months ago - ETF Trends

SBIO Is a Good Place to Be for Biotech Innovation

While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare sect...

Other symbols: BBHIBBSBIO
10 months ago - ETF Trends

Top and Flop ETFs At Midway Q1

We have highlighted the five best-performing zones and their ETFs halfway through first-quarter 2022.

Other symbols: ARKKBDRYOIHPALLPFIX
10 months ago - Zacks Investment Research

Biotech M&A Could Finally Perk Up in 2022

Broadly speaking, mergers and acquisitions in the healthcare sector were steady in 2021, but for many investors, there weren't enough aimed at smaller biotechnology companies. As is often the case, mark...

Other symbols: BBHIBBSBIO
1 year ago - ETF Trends

Smaller Biotech Stocks Ready to Perk Up

If there's an asset class that's looking forward to 2022, it's small- and mid-cap (SMID) biotechnology stocks because that group dealt with a variety of headwinds this year. However, there are more reas...

Other symbols: SBIOBBHIBB
1 year ago - ETF Trends

Biotech Stocks Have Colds, but They Can Heal

This year hasn't been kind to biotechnology stocks and related exchange traded funds. The headwinds faced by these assets were ratcheted up last week when the Biden administration revealed plans to purs...

Other symbols: SBIOBBHIBB
1 year ago - ETF Trends

Finding Synergy With SPY

Looking for the perfect partner for the world's largest ETF.

1 year ago - ETFcom

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

Other symbols: CNCRPFESBIOXBI
1 year ago - Zacks Investment Research